| Cat. No. |
Product Name |
Information |
| PC-73400 |
Atinvicitinib
JAK inhibitor
|
Atinvicitinib is a pyrazole compound and JAK inhibitor with IC50 of 0.4, 6 and 13 nM against JAK1, JAK2, and TYK2, less potent for JAK3 (IC50=1130 nM), has the potential for the research of atopic dermatitis. |
| PC-73205 |
Cerdulatinib hydrochloride
dual SYK/JAK inhibitor
|
Cerdulatinib (PRT062070) is a potent, ATP-competitive, orally active dual SYK/JAK inhibitor with IC50 of 32 nM (Syk), 0.5-12 nM (JAK1/2/3, Tyk2). |
| PC-73204 |
Cerdulatinib
dual SYK/JAK inhibitor
|
Cerdulatinib (PRT062070) is a potent, ATP-competitive, orally active dual SYK/JAK inhibitor with IC50 of 32 nM (Syk), 0.5-12 nM (JAK1/2/3, Tyk2). |
| PC-73190 |
Baricitinib
JAK1/JAK2 inhibitor
|
Baricitinib (LY3009104, INCB028050) is a potent, selective and orally bioavailable JAK1/JAK2 inhibitor with IC50 of 5.9/5.7 nM, respectively. |
| PC-72341 |
TD-1473
Pan-JAK inhibitor
|
TD-1473 (Izencitinib, TD1473, JNJ 8398) is a potent, selective, oral gut-selective pan-JAK inhibitor with pKi of 10.0/10.0/8.8/9.5 for human recombinant JAK1, JAK2, JAK3 and TYK2. |
| PC-72038 |
NDI-031407
TYK2 inhibitor
|
NDI-031407 (NDI 031407) is a novel potent, selective TYK2 inhibitor with IC50 of 0.21 nM in radiometric assays, 20 fold selectivity over JAK3 (4.2 nM), 147 fold for JAK2 (31 nM), and 220 fold for JAK1 (46 nM). |
| PC-38034 |
FM479
|
FM-479 is an FM-381 structural analog, the negative control of FM-381 and has no activity on JAK3 or other kinases.. |
| PC-36069 |
ZT55
|
ZT55 (JAK inhibitor ZT55) is a novel potent, highly-selective tyrosine kinase JAK2 inhibitor with IC50 of 31 nM. |
| PC-35842 |
SAR-20347
|
SAR-20347 (SAR20347) is a potent, selective inhibitor of JAK1 and Tyk2 with IC50 of 59 and 13 nM in TR-FRET assays, shows selectivity against JAK2 and JAK3 (IC50>800 nM). |
| PC-35502 |
JAK2 inhibitor G5-7
|
JAK2 inhibitor G5-7 is a small molecule, allosteric JAK2 inhibitor that selectively inhibits JAK2-mediated phosphorylation and activation of EGFR and STAT3 by binding to JAK2. |
| PC-43343 |
LY2784544
|
LY2784544 (Gandotinib) is a potent, selective and ATP-competitive inhibitor of JAK2V617F, effectively inhibits JAK2V617F-driven signaling and cell proliferation in Ba/F3 cells (IC50=20 and 55 nM, respectively). |
| PC-63194 |
Atiprimod dihydrochloride
|
Atiprimod (SKF 106615, Azaspirane) is a potent, orally bioavailable JAK2 inhibitor, inhibits phosphorylation of JAK2 and the downstream STAT3 and STAT5 pathways. |
